Project/Area Number |
15K07974
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Pharmacology in pharmacy
|
Research Institution | Tokyo University of Science |
Principal Investigator |
Oka Jun-Ichiro 東京理科大学, 薬学部薬学科, 教授 (40134613)
|
Co-Investigator(Kenkyū-buntansha) |
山下 親正 東京理科大学, 薬学部薬学科, 教授 (30622188)
|
Co-Investigator(Renkei-kenkyūsha) |
HAMADA Sachie (SASAKI Sachie) 東京理科大学, 薬学部, ポストドクトラル研究員 (00399320)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Keywords | 経鼻投与 / 中枢移行性 / GLP-2 / GLP-1 / Neuromedin U / Oxytocin / うつ病 / 認知症 |
Outline of Final Research Achievements |
The intranasally administered GLP-2 derivative containing cell-penetrating peptides and a penetration-accelerating sequence induced antidepressant-like effects in refractory depression model mice. Similarly, intranasally administered GLP-1, neuromedin U or oxytocin derivatives induced memory improving effects in amnesia model mice. These derivatives are probably delivered to the brain through the trigeminal nerve from the respiratory epithelium in the nasal mucosa. These results indicate that the derivatives may useful in the clinical treatment of psychiatric and neurological disorders by the intranasal administration.
|